Literature DB >> 10232530

Therapeutic modalities for the management of cerebral vasospasm: timing of endovascular options.

R H Rosenwasser1, R A Armonda, J E Thomas, R P Benitez, P M Gannon, J Harrop.   

Abstract

OBJECTIVES: To determine if a window of time could be defined during which angioplasty would be most effective in reversing neurological decline and ultimately improving outcome.
METHODS: Of a group of 466 patients, 93 underwent endovascular management of clinical vasospasm that was medically refractory. Eighty-four of the 93 patients were available for follow-up for at least 6 months. All patients underwent mechanical angioplasty using compliant microballoon systems and, if distal spasm was present, the administration of papaverine.
RESULTS: Fifty-one patients underwent endovascular management within a 2-hour window, and 33 patients underwent treatment more than 2 hours after the development of their symptoms. Compared with the group treated more than 2 hours after neurological decline (P < 0.01; chi2 = 8.02), the group that underwent endovascular management within a 2-hour window after the development of symptoms demonstrated sustained clinical improvement.
CONCLUSION: When a patient develops symptomatic vasospasm and is unresponsive to traditional measures of critical care management, angioplasty may be effective in improving the patient's neurological status if this procedure is performed as early as possible. The results indicate that a 2-hour window may exist for restoration of blood flow to ultimately improve the patient's outcome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10232530     DOI: 10.1097/00006123-199905000-00022

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  38 in total

1.  Vasospasm and delayed consequences.

Authors:  S Bracard; E Schmitt
Journal:  Interv Neuroradiol       Date:  2008-10-09       Impact factor: 1.610

2.  Role of CT perfusion imaging in the diagnosis and treatment of vasospasm.

Authors:  Edward D Greenberg; Y Pierre Gobin; Howard Riina; Carl E Johnson; Apostolos J Tsiouris; Joseph Comunale; Pina C Sanelli
Journal:  Imaging Med       Date:  2011-06-01

3.  The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  Abutaher M Yahia; Jawad F Kirmani; Adnan I Qureshi; Lee R Guterman; L Nelson Hopkins
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Relative changes in flow velocities in vasospasm after subarachnoid hemorrhage: a transcranial Doppler study.

Authors:  Neeraj S Naval; Carole E Thomas; Victor C Urrutia
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 5.  Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage.

Authors:  James K Liu; William T Couldwell
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

6.  Cerebrovasospasm following endoscopic cerebrospinal fluid leak repair.

Authors:  Jason P Hunt; Trent Richards
Journal:  Skull Base       Date:  2010-09

7.  Reversible cerebral vasoconstriction syndrome: treatment with combined intra-arterial verapamil infusion and intracranial angioplasty.

Authors:  H Farid; J K Tatum; C Wong; V V Halbach; S W Hetts
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-27       Impact factor: 3.825

Review 8.  Clinical Presentation, Imaging, and Management of Complications due to Neurointerventional Procedures.

Authors:  Matthew C Davis; John P Deveikis; Mark R Harrigan
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

Review 9.  [Aneurysmal subarachnoid hemorrhage. Significance and complications].

Authors:  A S Sarrafzadeh; U Kaisers; W Boemke
Journal:  Anaesthesist       Date:  2007-09       Impact factor: 1.041

10.  Combined endovascular treatment for both intracranial aneurysm and symptomatic vasospasm.

Authors:  Yuichi Murayama; Joon K Song; Ken Uda; Y Pierre Gobin; Gary R Duckwiler; Satoshi Tateshima; Aman B Patel; Neil A Martin; Fernando Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.